develop
antimicrobi
agent
key
achiev
modern
medicin
howev
overus
led
increas
incid
infect
due
antibioticresist
microorgan
quantit
figur
current
econom
health
impact
antimicrobi
resist
scant
clearli
grow
challeng
requir
time
action
action
educ
ethic
econom
polit
level
import
first
step
would
increas
public
awar
willing
take
necessari
measur
curb
resist
henc
studi
need
would
provid
solid
quantit
data
societ
impact
antibiot
resist
review
discuss
complex
resist
identifi
main
driver
propos
measur
contain
european
scale
wtm
jansen
report
antibiot
resist
gener
cover
singl
topic
field
review
aim
demonstr
complex
resist
identifi
main
factor
involv
propos
adequ
measur
contain
resist
european
scale
antibiot
resist
increasingli
recogn
public
health
concern
gener
consid
consequ
wide
use
misus
antibiot
current
coher
action
taken
address
problem
univers
medic
center
utrecht
found
strateg
council
antibiot
resist
europ
score
ascertain
current
situat
provid
roadmap
curb
antibiot
resist
europ
achiev
goal
score
organ
sever
symposia
attend
european
expert
antibiot
resist
includ
microbiologist
infecti
diseas
specialist
pharmaceut
industri
scientist
meet
questionnair
antibiot
resist
continu
flow
comment
suggest
via
email
publicli
avail
report
literatur
summar
wide
support
consensusbas
report
verhoef
et
al
review
base
score
report
recent
inform
literatur
data
major
european
surveil
network
contrast
lifethreaten
infect
regard
diseas
past
given
avail
success
antibiot
vaccin
miscalcul
today
infecti
diseas
back
spotlight
antimicrobi
resist
increasingli
hamper
success
therapi
case
bacteri
infect
problem
encount
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococci
vre
multiresist
streptococcu
pneumonia
multiresist
mycobacterium
tuberculosi
intrins
multiresist
pseudomona
aeruginosa
acinetobact
baumanii
multiresist
enterobacteriacea
includ
extendedspectrum
strain
esbl
spite
great
geograph
variat
resist
level
antibiot
slow
increas
antibiot
resist
pathogenantibiot
regimen
combin
resist
clearli
rise
major
human
pathogen
fig
resist
level
empir
use
antibiot
propos
guid
switch
therapi
gemmel
et
al
noon
therefor
extrapol
antibiot
resist
trend
fig
predict
empir
therapi
pathogen
becom
problemat
near
futur
anoth
import
observ
everi
current
market
antibiot
alreadi
face
bacteria
acquir
resist
newli
introduc
antibiot
therefor
matter
resist
aris
unfortun
last
decad
new
antibiot
class
discov
expert
pessimist
introduct
new
class
near
futur
therefor
effort
urgent
need
slow
resist
develop
exist
antibiot
gramposit
bacteria
staphylococcu
aureu
aureu
common
human
pathogen
virtu
part
normal
skin
flora
one
greatest
concern
regard
antibiot
resist
mrsa
first
mrsa
emerg
shortli
introduct
penicillin
methicillin
earli
howev
late
seri
epidem
mrsa
strain
evolv
sinc
spread
throughout
hospit
world
communityassoci
ca
mrsa
emerg
rapidli
spread
hospit
commun
document
molecular
epidemiolog
studi
involv
puls
field
gel
electrophoresi
pfge
kollef
micek
zetola
et
al
pfge
suitabl
tool
investig
mrsa
outbreak
high
discriminatori
power
robinson
enright
ca
mrsa
strain
threat
healthi
individu
typic
carri
pantonvalentin
leukocidin
toxin
associ
necrotis
pneumonia
genesti
et
al
complet
genom
sequenc
epidem
ca
mrsa
clone
major
sourc
communityacquir
infect
usa
canada
europ
reveal
presenc
addit
virul
element
name
arginin
catabol
mobil
element
encod
arginin
deiminas
pathway
oligopeptid
permeas
system
could
contribut
fit
clone
diep
et
al
multilocu
sequenc
type
mlst
shown
hospitalacquir
ha
mrsa
strain
cluster
five
domin
lineag
wherea
ca
mrsa
genotyp
dispers
robinson
enright
resist
mrsa
confer
meca
gene
staphylococc
chromosom
cassett
mec
sccmec
five
type
sccmec
describ
sccmec
ii
iii
associ
ha
mrsa
wherea
sccmec
type
iv
v
mainli
found
ca
mrsa
sinc
sccmec
iv
v
contain
resist
gene
except
meca
ca
mrsa
less
multiresist
ha
mrsa
hanssen
ericson
sollid
remark
us
strain
usa
sequenc
type
usa
sequenc
type
predomin
ca
mrsa
wherea
australia
europ
mainli
sequenc
type
type
found
respect
chamber
vandenesch
et
al
success
treatment
mrsa
vancomycin
hamper
emerg
glycopeptid
intermediateresist
aureu
strain
appelbaum
cui
et
al
first
report
vancomycinresist
mrsa
strain
europ
japan
usa
franc
tenov
mcdonald
new
antibiot
linezolid
quinupristindalfopristin
daptomycin
effect
mrsa
although
latter
two
antibiot
recommend
pulmonari
infect
pharmacokinet
reason
schmidtioana
et
al
significantli
resist
linezolid
daptomycin
recent
report
aureu
gale
et
al
marti
et
al
skiest
pneumonia
import
caus
communityacquir
pneumonia
second
common
caus
bacteri
mening
past
pneumonia
exquisit
suscept
penicillin
penicillin
erythromycin
resist
imped
success
treatment
pneumococc
infect
tleyjeh
et
al
addit
rapid
increas
quinolon
resist
rate
report
may
hamper
use
antibacteri
class
erad
penicillinresist
pneumococci
deshpand
et
al
given
document
treatment
failur
penicillin
although
rare
macrolid
quinolon
cephalosporin
cefotaxim
ceftriaxon
recommend
treatment
pneumococc
pneumonia
peterson
cephalosporinresist
pneumococc
infect
may
effect
treat
combin
ceftriaxon
rifampicin
vancomycin
ribe
et
al
enterococci
consid
resist
reservoir
pathogen
although
hardli
virul
increas
health
concern
given
intrins
resist
mani
antibiot
includ
cephalosporin
abil
acquir
resist
remain
antibiot
enterococci
readili
gain
resist
wide
rang
antibiot
includ
fluoroquinolon
ampicillin
tetracyclin
macrolid
chloramphenicol
trimethoprim
quinopristindalfopristin
vancomycin
leav
treatment
option
bonten
et
al
recent
resist
daptomycin
report
long
et
al
increas
number
sever
ill
patient
combin
increas
use
agent
may
fuel
clinic
import
multiresist
enterococci
enterococcu
faecium
consid
less
pathogen
less
frequent
isol
enterococcu
faecali
nevertheless
grow
clinic
problem
potenti
develop
resist
multipl
antibiot
includ
linezolid
bonora
et
al
daptomycin
combin
rifampicin
may
new
effect
therapi
multiresist
enterococci
pankey
et
al
mani
gramneg
rod
opportunist
nosocomi
pathogen
resist
rate
vari
among
differ
speci
antibiot
escherichia
coli
proteu
mirabili
among
least
resist
wherea
enterobact
spp
klebsiella
spp
p
aeruginosa
show
greater
innat
acquir
resist
acinetobact
stenotrophomona
low
virul
tend
multidrug
resist
fournier
et
al
looney
new
glycylcyclin
antibiot
tigecyclin
hold
promis
efficaci
multiresist
speci
decreas
suscept
common
among
proteu
spp
p
aeruginosa
wherea
isol
decreas
suscept
found
klebsiella
enterobact
spp
sader
et
al
sader
et
al
zhanel
et
al
import
resist
mechan
antibiot
increasingli
found
enterobacteriacea
extendedspectrum
esbl
paterson
bonomo
esbl
discov
europ
earli
widespread
use
extend
spectrum
cephalosporin
typic
esbl
deriv
class
sensit
clavulan
acid
sulbactam
locat
plasmid
transfer
within
differ
bacteri
speci
confer
resist
extendedspectrum
cephalosporin
paterson
bonomo
addit
plasmidmedi
ampc
emerg
resist
profil
similar
esbl
pfaller
segreti
current
carbapenem
recommend
therapi
infect
esblproduc
bacteria
howev
use
carbapemen
associ
emerg
carbapenemresist
stenotrophomona
spp
pseudomona
spp
enterobacteriacea
paterson
bonomo
rupp
fey
gene
encod
esbl
frequent
found
part
integronlik
structur
togeth
resist
gene
bradford
esbl
produc
strain
frequent
associ
quinolon
resist
poirel
et
al
resist
fluoroquinolon
aris
result
mutat
target
enzym
dna
gyras
topoisomeras
iv
chang
drug
entri
efflux
plasmid
produc
qnr
protein
protect
quinolon
target
inhibit
jacobi
increas
preval
quinoloneresist
neisseria
gonorrhoea
observ
western
world
wherea
resist
pathogen
use
associ
travel
asia
nowaday
quinoloneresist
n
gonorrhoea
may
spread
endem
certain
risk
group
macomb
et
al
martin
et
al
resist
pattern
necessit
replac
inexpens
oral
ciprofloxacin
expens
inject
ceftriaxon
treatment
gonorrhea
roy
et
al
tuberculosi
tb
remain
common
bacteri
caus
death
singl
infecti
agent
adult
worldwid
estim
million
death
report
annual
wherea
million
new
infect
occur
year
mostli
develop
world
hiv
pandem
revers
steadi
declin
tb
case
develop
world
tuberculosi
requir
treatment
combin
three
four
agent
least
month
monotherapi
rapidli
lead
resist
due
select
spontan
mutant
ginsburg
et
al
kaufmann
mcmichael
low
qualiti
antibiot
develop
world
lack
patient
complianc
also
contribut
problem
past
year
global
microbi
health
threatsbioterror
sever
acut
respiratori
syndrom
sar
avian
influenza
receiv
far
polit
public
attent
antimicrobi
resist
acut
visibl
danger
pose
bioterror
sar
led
array
intern
measur
acceler
creation
european
centr
diseas
prevent
control
ecdc
gouvra
although
antimicrobi
resist
may
perceiv
less
acut
littl
known
impact
mortal
econom
cost
incur
societi
mani
studi
perform
attribut
mortal
econom
cost
studi
difficult
interpret
due
mani
confound
andor
lack
tabl
analog
antimicrobi
resist
greenhous
effect
analog
need
integr
approach
intergener
longterm
vision
current
impact
unclear
controversi
impact
studi
anticip
problem
effect
may
irrevers
precautionari
measur
appropri
control
ie
infect
suscept
bacteria
data
need
public
polit
debat
issu
requir
determin
costeffect
measur
contain
antimicrobi
resist
coast
et
al
coast
et
al
mcconnel
schoch
antimicrobi
resist
share
properti
greenhous
effect
tabl
complex
global
intergener
problem
current
societ
burden
problem
larg
unknown
may
rel
mild
howev
extrapol
current
trend
predict
possibl
disastr
consequ
continu
uncheck
moreov
extent
futur
problem
revers
uncertain
properti
summar
paradox
antimicrobi
resist
time
action
need
prevent
possibl
doom
scenario
time
concret
figur
current
impact
antimicrobi
resist
lack
surprisingli
littl
known
actual
clinic
econom
impact
antibiot
resist
paragraph
simpl
model
mrsa
bacteremia
present
use
estim
excess
econom
clinic
cost
infect
compar
mssa
bacteremia
studi
european
public
health
impact
antimicrobi
resist
perform
recent
data
attribut
risk
mortal
due
methicillinresist
mrsa
bacteremia
cosgrov
et
al
data
european
antimicrobi
resist
surveil
system
earss
becom
avail
european
antimicrobi
resist
surveil
system
combin
provid
guestim
impact
mrsa
bacteremia
european
scale
public
health
impact
mrsa
bacteremia
directli
relat
absolut
number
bloodstream
infect
mrsa
ni
proport
mortal
pm
repres
fraction
patient
die
mrsa
bacteremia
excess
mortal
attribut
methicillin
resist
infect
per
se
within
group
patient
depend
attribut
risk
resist
ar
ar
function
rel
risk
rr
defin
ar
rr
rr
excess
mortal
due
mrsa
bacteremia
thu
formul
ni
pm
ar
formula
total
number
mrsa
bacteremia
ni
european
union
estim
case
deriv
earss
data
european
antimicrobi
resist
surveil
system
fluit
et
al
eu
popul
size
data
obtain
cia
world
factbook
central
intellig
agenc
usa
mean
report
mortal
rate
mrsa
bacteremia
cosgrov
et
al
metaanalysi
estim
pool
rel
risk
rr
death
mrsa
bacteremia
ci
cosgrov
et
al
use
formula
total
attribut
mortal
due
mrsa
bacteremia
european
union
estim
approxim
death
likewis
econom
impact
mrsa
bacteremia
ec
product
absolut
number
mrsa
bloodstream
infect
ni
attribut
cost
per
infect
ac
ec
ni
ac
formula
sever
studi
estim
averag
attribut
cost
case
hospit
acquir
mrsa
bacteremia
around
abramson
sexton
cosgrov
et
al
mchugh
riley
excess
cost
mrsa
infect
mainli
origin
increas
durat
hospit
intens
care
unit
stay
use
formula
estim
number
mrsa
bacteremia
europ
may
thu
caus
attribut
cost
around
million
lack
detail
data
possibl
confound
factor
mean
figur
given
regard
first
exampl
resist
cost
estim
obvious
research
need
attribut
cost
mortal
econom
mrsa
bacteremia
improv
accuraci
figur
similarli
figur
extend
major
resist
pathogen
data
becom
avail
howev
base
estim
present
annual
cost
mrsa
bacteraemia
alon
would
alreadi
exceed
total
european
union
budget
antimicrobi
resist
research
european
commiss
even
wors
extrapol
current
rise
trend
antimicrobi
resist
suggest
real
problem
still
ahead
us
worst
case
scenario
ie
emerg
fulli
antimicrobialresist
microorgan
lead
situat
similar
preantimicrobi
era
would
enorm
impact
human
suffer
larg
financi
consequ
even
concern
fraction
common
microorgan
within
hospit
commun
broad
public
polit
awar
critic
set
prioriti
requir
contain
antimicrobi
resist
near
futur
surveil
antibiot
resist
need
determin
resist
level
trend
certain
geograph
area
inform
use
ensur
appropri
antibiot
prescript
detect
time
new
mechan
resist
monitor
intervent
report
pathogen
new
resist
phenotyp
vrsa
japan
us
appelbaum
underscor
import
european
surveil
network
obtain
time
inform
emerg
resist
pathogen
despit
mani
difficulti
much
gain
combin
effort
institut
broad
surveil
network
howev
initi
new
surveil
program
costli
altern
start
central
analysi
qualityassur
local
surveil
data
obtain
anyway
guid
antimicrobi
therapi
individu
patient
pharmaceut
industri
may
also
contribut
surveil
program
return
includ
newer
antibiot
earss
may
use
start
point
object
earss
collect
compar
reliabl
european
antimicrobi
resist
data
benefit
public
health
across
europ
earss
howev
limit
number
microorgan
particip
hospit
addit
hospit
microorgan
tuberculosi
need
includ
sinc
standard
methodolog
antibiot
suscept
determin
achiev
across
europ
qualiti
control
extrem
import
earss
data
combin
antibiot
consumpt
data
obtain
european
surveil
antibiot
consumpt
esac
http
wwwesacuaacb
mainaspx
c
gain
insight
link
antibiot
consumpt
resist
bronzwaer
et
al
despit
larg
number
surveil
program
littl
known
resist
reservoir
outsid
hospit
includ
nurs
home
kindergarten
food
veterinari
sector
environ
pet
danmap
danish
integr
antimicrobi
resist
monitor
research
programm
http
wwwkeepantibioticswork
comnewresourc
librarycfm
address
problem
antibioticresist
isol
anim
food
human
bager
antibiot
consumpt
data
food
anim
collect
accord
vetstat
programm
http
wwwdbmccouktech
infotech
reportsvetstat
reportasp
record
herd
stege
et
al
ideal
veterinari
sector
follow
danmapvetstat
approach
environ
may
also
function
resist
reservoir
costa
et
al
describ
presenc
antibiot
resistom
among
actinomycet
dcosta
et
al
soildwel
bacteria
natur
resist
wide
rang
antibiot
clinic
use
produc
enzym
inactiv
least
antibiot
includ
rifampicin
synercid
daptomycin
gene
encod
resist
element
may
horizont
transmit
human
pathogen
event
may
occur
vancomycin
resist
determin
vre
reservoir
dedic
surveil
program
requir
link
surveil
network
integr
data
conduct
earss
esac
first
step
ultim
surveil
may
central
perform
part
european
center
diseas
prevent
control
interest
antibiot
consumpt
rais
evolutionari
concept
antibiot
provid
select
pressur
need
emerg
spread
bacteri
resist
consequ
modif
antibiot
consumpt
may
import
way
influenc
incid
preval
resist
bacteria
sinc
emerg
resist
intrins
link
use
antibiot
complet
prevent
resist
imposs
defin
interag
task
forc
antimicrobi
resist
prudent
use
antibiot
encourag
maxim
therapeut
impact
minim
toxic
develop
resist
prudent
use
therefor
simpli
impli
reduct
antibiot
consumpt
prevent
misus
overus
way
life
span
singl
antibiot
extend
allow
time
develop
new
antibiot
implement
approach
combat
antimicrobi
resist
prudent
use
antibiot
may
especi
import
resist
level
still
low
declin
resist
treatment
cessat
much
slower
emerg
persist
resist
may
depend
fit
cost
resist
linkag
multipl
resist
gene
mobil
element
andersson
collect
consumpt
data
european
scale
conduct
esac
huge
variat
local
nation
european
antibiot
prescript
practis
percentag
patient
given
antibiot
may
vari
gener
aboveaverag
consumpt
antibiot
occur
mediterranean
countri
itali
spain
wherea
consumpt
averag
northern
europ
besid
volum
differ
also
differ
trend
choic
therapi
mediterranean
countri
tend
prescrib
broadspectrum
antibiot
coenen
et
al
final
consider
selfmed
may
occur
southern
europ
vaananen
et
al
prudent
use
antibiot
achiev
educ
main
tool
improv
antibiot
prescript
gener
public
farmer
often
largescal
user
antimicrobi
agent
politician
healthcar
worker
often
limit
knowledg
extent
antibioticresist
problem
gener
fulli
awar
problem
associ
antibiot
use
medic
microbiologist
infecti
diseas
specialist
play
central
role
educ
howev
even
though
union
european
medic
specialist
drawn
train
record
train
program
candid
train
medic
microbiolog
european
societi
clinic
microbiolog
infecti
diseas
escmid
organ
cours
traine
europ
train
specialist
harmon
within
eu
grundmann
goossen
lack
harmon
led
differ
opinion
problem
antibiot
resist
harmon
achiev
provid
scientif
evid
therefor
monitor
antibiot
consumpt
combin
surveil
necessari
acquir
insight
complex
interact
antibiot
use
resist
data
obtain
also
use
feedback
prescrib
influenc
behaviour
increas
public
awar
computerassist
decis
support
program
antimicrobi
prescript
may
aid
physician
accur
antibiot
prescript
combin
local
surveil
data
antimicrobi
suscept
program
tailor
made
advic
empir
drug
use
local
level
promis
result
report
stabil
reduc
antibiot
resist
decis
support
program
burk
pestotnik
sintchenko
et
al
prudent
use
antibiot
greatli
aid
develop
rapid
diagnost
test
broadspectrum
empir
therapi
quickli
adjust
narrowspectrum
therapi
addit
rapid
accur
diagnosi
may
limit
spread
infect
diminish
use
antibiot
therebi
risk
emerg
resist
bacteria
molecular
biolog
techniqu
base
realtim
pcr
microarray
nanoparticl
technolog
potenti
provid
rapid
accur
diagnosi
bacteri
infect
rapid
test
particularli
use
provid
inform
appropri
antibacteri
therapi
peterson
dalhoff
cycl
antibiot
propos
strategi
limit
select
pressur
specif
antibiot
class
period
chang
standard
antibiot
regimen
patient
popul
howev
efficaci
strategi
still
highli
debat
van
loon
et
al
econom
perspect
antimicrobi
resist
consid
neg
extern
mean
societ
cost
criterion
manufactur
consumpt
antibiot
coast
et
al
level
willing
balanc
current
individu
benefit
perceiv
realagainst
futur
societ
cost
crucial
attempt
curb
antimicrobi
resist
econom
concept
deal
futur
societ
cost
antibiot
use
per
dose
annual
loss
loss
regard
virtual
price
tag
express
futur
societ
cost
singl
antibiot
prescript
cost
societi
due
increas
antimicrobi
resist
may
lead
use
expens
antibiot
increas
hospitalis
morbid
mortal
virtual
price
tag
depend
relat
antibiot
use
resist
annual
impact
resist
phelp
antibiot
price
tag
may
provid
indic
magnitud
resist
problem
relat
antibiot
use
provid
handl
measur
costeffect
measur
promot
prudent
use
antibiot
reduct
antimicrobi
use
may
also
requir
ethic
decis
put
societ
interest
individu
interest
consequ
patient
receiv
optim
treatment
order
curb
resist
respect
resist
similar
social
dilemma
tragedi
common
dilemma
refer
pastur
share
herdsman
individu
benefit
introduc
new
cow
owner
herder
societi
pay
prize
overgraz
foster
grundmann
conclus
defin
implement
prudent
use
antibiot
mani
ethic
polit
econom
research
question
remain
answer
ideal
antibiot
classifi
accordingli
use
firstchoic
antibiot
restrict
choic
antibiot
treat
resist
microorgan
reserv
antibiot
combat
lifethreaten
infect
framework
guidelin
prudent
use
antibiot
need
adapt
local
situat
approv
local
prescrib
implement
guidelin
strenuou
ongo
process
address
relev
parti
regularli
basi
predefin
outcom
indic
monitor
efficaci
grol
grimshaw
infect
control
import
compon
curb
antibiot
resist
wherea
prudent
use
antibiot
reduc
emerg
spread
antibioticresist
bacteria
infect
prevent
measur
mainli
control
spread
antibioticresist
bacteria
estim
adher
proper
infect
control
measur
may
reduc
nosocomi
infect
haley
et
al
infect
prevent
polici
particular
focu
number
specif
nosocomi
infect
surgic
site
infect
infect
relat
intravascular
devic
nosocomi
pneumonia
urinari
tract
infect
verhoef
et
al
societi
healthcar
epidemiolog
america
shea
formul
guidelin
prevent
spread
mrsa
vre
addit
contact
precaut
patient
colon
infect
multiresist
organ
activ
surveil
necessari
identifi
sourc
control
transmiss
muto
et
al
face
worldwid
increas
multiresist
bacteria
addit
guidelin
need
resist
pathogen
well
includ
penicillinresist
pneumonia
esbl
produc
enterobacteriacea
kluytmansvandenbergh
et
al
dutch
work
parti
infect
prevent
issu
guidelin
prevent
nosocomi
transmiss
highli
resist
pathogen
guidelin
provid
specif
definit
highli
resist
microorgan
human
pathogen
potenti
spread
hospit
acquir
antimicrobi
resist
hamper
empir
therapi
depend
class
highli
resist
microorgan
specif
isol
measur
activ
surveil
contact
trace
conduct
kluytmansvandenbergh
et
al
eventu
success
nation
implement
obtain
result
need
evalu
come
year
may
serv
blueprint
formul
guidelin
broader
european
scale
one
profound
infect
prevent
polici
searchanddestroy
polici
mrsa
polici
includ
identif
treatment
carrier
isol
cohort
mrsaposit
patient
strict
hygien
polici
screen
contact
person
closur
ward
countri
use
polici
netherland
scandinavia
low
mrsa
preval
indic
success
approach
wertheim
et
al
polici
costli
littl
evid
necess
efficaci
individu
compon
mathemat
model
suggest
subset
measur
may
suffic
control
mrsa
preval
lowendem
set
model
indic
highendem
set
appropri
measur
reduc
mrsa
level
bootsma
et
al
pan
et
al
seriou
threat
feasibl
polici
emerg
mrsa
commun
may
huge
consequ
capac
hospit
screen
isol
patient
order
maintain
search
destroy
strategi
nevertheless
searchanddestroy
strategi
consid
new
pathogenresist
combin
vrsa
infect
prevent
measur
also
includ
vaccin
program
commun
exampl
vaccin
program
may
contribut
reduct
resist
applic
pneumococc
conjug
vaccin
children
whitney
klugman
one
main
obstacl
infect
prevent
lack
evidencebas
measur
consequ
lack
consensu
infect
prevent
polici
mention
solid
evid
efficaci
search
destroy
lack
anoth
exampl
ongo
discuss
benefit
close
versu
open
suction
system
prevent
cathet
relat
infect
clearli
studi
evidencebas
intervent
need
use
formul
guidelin
order
properli
address
effect
infectionprevent
measur
studi
perform
accord
effect
practis
organ
care
epoc
methodolog
mathemat
model
may
aid
predict
success
costeffect
infect
prevent
polici
smith
et
al
design
presenc
implement
infectioncontrol
prevent
protocol
becom
mandatori
hospit
near
futur
verhoef
et
al
new
antibiot
market
last
decad
variat
common
theme
resist
antibiot
develop
rel
easili
homolog
older
antibiot
class
new
class
antibiot
oxazolidinon
ad
arsen
past
year
wilcox
dearth
new
antibiot
form
import
health
threat
europ
next
year
larg
pharmaceut
compani
move
away
field
antibiot
develop
shlae
sever
reason
worrisom
phenomenon
develop
new
antibiot
cost
million
take
year
yield
product
use
brief
period
target
prone
develop
resist
addit
new
drug
face
restrict
polici
toward
use
incent
improv
compani
reinvest
antibiot
develop
sever
measur
consid
faster
registr
process
new
lastresort
antibiot
abraham
patent
extens
join
nonprofit
research
platform
nathan
subsidi
taxincent
nathan
goldberg
action
consid
stimul
develop
new
antibiot
although
larg
pharmaceut
compani
ceas
antibiot
develop
posit
trend
gap
least
partial
fill
small
biotech
compani
smaller
compani
howev
need
partner
perform
clinic
trial
compani
use
varieti
strategi
develop
new
antibiot
genomicsbas
approach
screen
natur
product
librari
fig
tradit
new
antibiot
identifi
sourc
actinomycet
fungi
soil
sampl
spong
larg
collect
individu
compound
phage
lytic
enzym
regain
interest
highli
specif
antibacteri
molecul
brown
howev
narrow
host
rang
emerg
bacteri
resist
failur
achiev
high
phage
polypeptid
concentr
site
infect
import
limit
genom
approach
reveal
rang
new
potenti
bacteriaspecif
target
target
may
compris
fig
simplifi
scheme
differ
rout
develop
new
class
antibiot
targetbas
approach
impli
develop
new
antibacteri
start
uniqu
bacteri
target
target
may
compris
essenti
accessori
eg
virul
gene
limit
number
broadspectrum
target
may
exist
compoundbas
approach
aim
identifi
new
lead
compound
mean
screen
compound
librari
human
bacteri
phage
peptid
function
vitro
assay
principl
small
molecul
better
drug
candid
exampl
peptid
thu
result
target
small
molecul
peptid
translat
nonprotein
lead
compound
involv
complex
technolog
like
structur
biolog
computerassist
drug
design
combinatori
chemistri
next
cycl
lead
compound
optimis
function
minim
side
effect
undesir
pharmacokinet
dynam
properti
essenti
gene
loss
function
lethal
bacterium
accessori
gene
virul
gene
use
structur
biolog
combinatori
chemistri
librari
lead
compound
gener
examin
interact
bacteri
target
theori
genomicsbas
approach
allow
ration
design
antibiot
novel
broadspectrum
target
reduc
probabl
emerg
resist
chalker
lunsford
practic
howev
translat
lead
compound
novel
drug
limit
success
far
technolog
still
infanc
date
singl
market
antibacteri
agent
discov
approach
major
bottleneck
gener
suffici
variant
lead
compound
predict
improv
efficaci
toxic
hugh
anoth
limit
genomicsbas
approach
yield
protein
target
wherea
import
class
antibiot
glycopeptid
act
nonprotein
target
summari
econom
incent
pharmaceut
industri
poor
also
success
rate
find
new
antibiot
gener
disappoint
may
reflect
insuffici
technolog
base
translat
target
natur
compound
new
antibiot
schmid
antimicrobi
resist
crossbord
issu
although
sever
network
arisen
address
issu
relat
antibiot
resist
eu
recent
start
develop
joint
european
polici
council
european
union
issu
statement
antimicrobi
resist
requir
cohes
approach
european
level
bronzwaer
et
al
sinc
europ
share
consequ
antimicrobi
resist
also
share
effort
contain
problem
given
global
dimens
complex
problem
concert
approach
need
henc
subsidiar
principl
state
action
requir
european
approach
proven
superior
nation
approach
warrant
implement
strong
european
polici
antibiot
resist
european
commiss
propos
commun
strategi
antimicrobi
resist
consist
four
key
compon
surveil
prevent
research
product
develop
intern
cooper
surveil
action
strengthen
surveil
network
european
level
antimicrobi
resist
antibiot
consumpt
data
prevent
action
includ
educ
campaign
infect
prevent
program
particular
vaccin
reduct
antibiot
selfmed
research
action
encourag
develop
new
antimicrobi
agent
altern
treatment
vaccin
rapid
reliabl
diagnost
test
final
eu
seek
intern
cooper
especi
promot
ration
use
antibiot
bronzwaer
et
al
anoth
import
step
toward
unifi
approach
antimicrobi
resist
recent
foundat
ecdc
also
power
field
antimicrobi
resist
clearli
eu
health
care
specialist
recogn
threat
antimicrobi
resist
howev
public
awar
remain
low
european
budget
address
complex
issu
guestim
surplu
econom
cost
mrsa
bacteremia
suggest
annual
cost
alon
alreadi
exceed
total
european
union
budget
antimicrobi
resist
research
european
commiss
suffici
polit
resolv
implement
effect
countermeasur
crucial
tackl
resist
problem
import
prerequisit
increas
public
awar
resist
problem
put
higher
european
nation
polit
agenda
hamper
lack
quantit
data
impact
resist
public
health
henc
first
prioriti
obtain
data
fig
although
new
class
antibiot
definit
need
econom
scientif
obstacl
may
hamper
develop
next
year
thu
focu
measur
prolong
life
current
new
antibi
fig
intervent
measur
effect
resist
level
import
relat
relev
outcom
paramet
colour
scale
yellow
red
indic
need
lowto
highprior
research
respect
infect
prevent
measur
includ
hygienecontrol
isol
polici
hospit
vaccin
program
commun
veterinari
sector
antibiot
develop
impli
need
better
technolog
order
develop
new
antibiot
altern
strategi
antibiot
use
refer
prudent
use
hospit
restrict
use
commun
ie
better
complianc
prohibit
overthecount
sale
antibiot
therapeut
use
veterinari
sector
standard
evidencebas
guidelin
educ
program
healthcar
profession
public
need
implement
intervent
measur
welldesign
standard
surveil
program
need
studi
costeffect
intervent
measur
hospit
commun
resist
reservoir
veterinari
sector
resist
level
turn
link
relev
outcom
paramet
like
mortal
morbid
econom
cost
resist
costeffect
intervent
measur
final
resist
dynam
analys
relat
intervent
measur
use
mathemat
model
spread
mechan
resist
address
coupl
resist
data
genet
background
strain
otic
intervent
strategi
research
need
translat
evidencebas
guidelin
implement
eu
final
much
fundament
knowledg
requir
understand
spread
fit
resist
bacteria
genet
level
base
argument
essenti
area
research
priorit
follow
determin
burden
resist
term
mortal
econom
impact
b
determin
effect
infectionprevent
antibioticus
measur
curb
resist
c
develop
improv
technolog
andor
altern
strategi
acquir
new
class
antibiot
altern
like
immuneenhanc
compound
examin
fit
resist
virul
gene
spread
clonal
horizont
transfer
resist
microb
among
differ
resist
reservoir
includ
hospit
commun
veterinari
sector
four
research
area
obvious
interdepend
suggest
prioriti
simpli
reflect
certain
focu
futur
research
area
antimicrobi
resist
complex
global
intergener
problem
requir
time
action
given
potenti
enorm
impact
human
health
mani
studi
group
set
investig
resist
problem
nation
program
adopt
cope
problem
eu
involv
effort
howev
usual
limit
scope
time
fund
wherea
medic
expert
seem
will
tackl
problem
verhoef
et
al
polit
willing
provid
incent
necessari
legisl
crucial
curb
resist
thorough
understand
societ
impact
antibiot
resist
clinic
econom
term
essenti
set
prioriti
although
local
singl
measur
taken
coher
approach
along
multipl
line
follow
battl
antimicrobi
resist
success
